Condition (MeSH)
Hyperkalemia
ClinicalTrials.gov lists 131 trials for Hyperkalemia or a narrower condition beneath it. AstraZeneca has the most among industry and government lead sponsors, with 29.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
131 of the 131 trials are tagged with Hyperkalemia itself; the rest are tagged with a narrower condition beneath it.
When did Hyperkalemia trials start? (22)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 19
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 7 |
| 2025 | 12 |
| 2024 | 10 |
| 2023 | 4 |
| 2022 | 14 |
| 2021 | 19 |
| 2020 | 8 |
| 2019 | 9 |
| 2018 | 4 |
| 2017 | 13 |
Showing 10 of 22 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 10 trials starting in 2026 and about 11 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 13 trials still running at the 2026-10-09 snapshot; registered median of 16 months across 92 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hyperkalemia trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 1/2 | 1 |
| Phase 2 | 17 |
| Phase 2/3 | 1 |
| Phase 3 | 23 |
| Phase 4 | 27 |
| Not applicable | 28 |
| Observational | 30 |
How many Hyperkalemia trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 7 |
| Recruiting | 12 |
| Enrolling by invitation | 2 |
| Active, not recruiting | 5 |
| Completed | 79 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hyperkalemia trials? (10)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| AstraZeneca | 29 |
| ZS Pharma, Inc. | 8 |
| Relypsa, Inc. | 7 |
| Vifor Pharma, Inc. | 3 |
| Waterstone Pharmaceutical (Wuhan) Co., LTD. | 3 |
Showing 5 of 10 sponsors.
Which drugs are being tested for Hyperkalemia? (9)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Sodium Zirconium Cyclosilicate | 26 |
| Patiromer | 14 |
| .spironolactone | 8 |
| Sodium polystyrene sulfonate | 3 |
| Lisinopril | 3 |
Showing 5 of 9 drugs.
Interventions as named in the registry (6)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Low dose losartan | 3 |
| Patiromer 8400 MG [Veltassa] | 2 |
| Salbutamol MDI | 2 |
| LOKELMA 5 GM Powder for Oral Suspension | 2 |
| WS016 Multiple Dose(12g) | 1 |
Showing 5 of 6 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hyperkalemia trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 262 | 17 |
| Renal failure acute | 222 | 4 |
| Cardiac failure congestive | 210 | 12 |
| Hyperkalaemia | 137 | 10 |
| Acute myocardial infarction | 115 | 11 |
Showing 5 of 10 adverse events.
Which publications cover Hyperkalemia? (212)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| AI-enabled electrocardiogram alert for potassium imbalance treatment: a pragmatic randomized controlled trial. | Nature communications | 2026 | Yes |
| Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalemia or High Risk of Hyperkalemia: Rationale and Design of the CARE-HK in HF Registry. | Journal of cardiac failure | 2025 | Yes |
| Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure. | Journal of the American College of Cardiology | 2025 | Yes |
| Sodium zirconium cyclosilicate versus sodium polystyrene sulfonate for treatment of hyperkalemia in hemodialysis patients: a randomized clinical trial. | BMC nephrology | 2025 | Yes |
| Prevalence, practice pattern, and mortality of hyperkalemia in Chinese patients undergoing hemodialysis in the visualize HD study. | Scientific reports | 2025 | Yes |
Showing 5 of 212 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.